Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2007/2008

Novartis120 enrolled

Overview

Annual trial for registration of trivalent split influenza vaccine with the strain composition of the season 2007/2008 in healthy adult and elderly subjects

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

120

Conditions

Seasonal Influenza Vaccine

Interventions

trivalent split influenza vaccineBIOLOGICAL

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * ≥ 18 years of age, mentally competent, willing and able to give informed consent prior to study entry * available for all the visits scheduled in the study and able to comply with all study requirements * in good health as determined by: medical history, physical examination, clinical judgment of the investigator Exclusion Criteria: * n/a

Locations (1)

Werksarztzentrum Herborn

Herborn, Germany

Outcomes

Primary Outcomes

evaluate the antibody response to each influenza vaccine antigen, as measured by haemagglutination inhibition (HI) test on Day 0 and on Day 21

evaluate safety of trivalent split influenza vaccine

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.